Scilex Holding Company (SCLX) Stock

Scilex Holding Company (SCLX) is a Healthcare stock trading at $7.11 (as of 2026-06-18), with a market capitalization of $75.57M and a trailing P/E of -0.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing prescription products for pain treatment. Its commercial product is ZTlido 1.8% (topical lidocaine for neuropathic pain related to post-herpetic neuralgia), and its pipeline includes SP-102 for epidural injections and SP-103 and SP-104 in clinical development for additional pain indications.

Valuation — source: SEC EDGAR (first-party)
Price	$7.11
Market Cap	$75.57M
P/E Ratio	-0.2
EV / EBITDA	-0.4
Price / Book	-0.30
Price / Sales	2.23
Dividend Yield	11.4%
DCF Value (model)	$-1.84
DCF Upside vs Price	-125.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$30.25M
Net Margin	-1236.4%
Return on Equity	154.9%
Debt / Equity	-0.32
Current Ratio	0.08
Revenue Growth (YoY)	-46.5%
EPS Growth (YoY)	6414.3%
FCF Growth (YoY)	-81.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-7.98 (distress)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-0.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-101.1%
vs Industry	-101.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($3.60M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Henry H. Ji
Employees	115
Country	US
IPO Date	2021-03-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.